NO20082919L - Heterosubstituted 3-alkylazetidine derivatives - Google Patents
Heterosubstituted 3-alkylazetidine derivativesInfo
- Publication number
- NO20082919L NO20082919L NO20082919A NO20082919A NO20082919L NO 20082919 L NO20082919 L NO 20082919L NO 20082919 A NO20082919 A NO 20082919A NO 20082919 A NO20082919 A NO 20082919A NO 20082919 L NO20082919 L NO 20082919L
- Authority
- NO
- Norway
- Prior art keywords
- disorders
- treatment
- useful
- compounds
- receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Nye forbindelser med strukturformel (I) er antagonister og/eller inversagonister mot reseptoren for cannabinoid-1 (CB1), og er anvendbare ved behandling, forebygging og undertrykkelse av sykdommer formidlet av CB1-reseptoren. Forbindelsene ifølge den foreliggende oppfinnelse er anvendbare som sentraltvirkende legemidler ved behandling av psykose, hukommelsessvikt, kognitive forstyrrelser, Alzheimers sykdom, migrene, nevropati, nevro-inflammatoriske forstyrrelser, inkludert multippel sklerose og GuillainBarre-syndrom, og de inflammatoriske følgesykdommer av viral encefalitt, cerebrale vaskulære forstyrrelser og hodetraume, angstforstyrrelser, stress, epilepsi, Parkinsons sykdom, bevegelsesforstyrrelser og schizofreni. Forbindelsene er også anvendbare til behandling av stoffmisbruksforstyrrelser, behandling av overvekt eller spiseforstyrrelser, samt behandling av astma, forstoppelse, kronisk intestinal pseudoobstruksjon og cirrhose i leveren.Novel compounds of structural formula (I) are antagonists and / or inverse agonists against the cannabinoid-1 (CB1) receptor, and are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. The compounds of the present invention are useful as centrally acting drugs in the treatment of psychosis, memory impairment, cognitive disorders, Alzheimer's disease, migraine, neuropathy, neuro-inflammatory disorders, including multiple sclerosis and GuillainBarre syndrome, disorders and head trauma, anxiety disorders, stress, epilepsy, Parkinson's disease, movement disorders and schizophrenia. The compounds are also useful for the treatment of substance abuse disorders, the treatment of overweight or eating disorders, as well as the treatment of asthma, constipation, chronic intestinal pseudo-obstruction and cirrhosis of the liver.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74018305P | 2005-11-28 | 2005-11-28 | |
| PCT/US2006/045328 WO2007062193A1 (en) | 2005-11-28 | 2006-11-22 | Heterocycle-substituted 3-alkyl azetidine derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20082919L true NO20082919L (en) | 2008-08-27 |
Family
ID=37779312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20082919A NO20082919L (en) | 2005-11-28 | 2008-06-27 | Heterosubstituted 3-alkylazetidine derivatives |
Country Status (15)
| Country | Link |
|---|---|
| EP (1) | EP1954692A1 (en) |
| KR (1) | KR20080073721A (en) |
| AR (1) | AR058199A1 (en) |
| BR (1) | BRPI0619018A2 (en) |
| CR (1) | CR10014A (en) |
| DO (1) | DOP2006000261A (en) |
| EC (1) | ECSP088477A (en) |
| IL (1) | IL191586A0 (en) |
| MA (1) | MA30086B1 (en) |
| NO (1) | NO20082919L (en) |
| PE (1) | PE20070647A1 (en) |
| RU (1) | RU2008126248A (en) |
| SV (1) | SV2009002917A (en) |
| TW (1) | TW200804317A (en) |
| WO (1) | WO2007062193A1 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
| EP2025674A1 (en) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituted tetra hydro naphthalines, method for their manufacture and their use as drugs |
| AU2008317482A1 (en) * | 2007-10-24 | 2009-04-30 | Merck Sharp & Dohme Corp. | Synthesis and crystalline forms of CB-1 antagonist/inverse agonist |
| EP2611788B1 (en) | 2010-09-03 | 2017-04-12 | University of Florida Research Foundation, Incorporated | Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use |
| WO2012120054A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2766349B1 (en) | 2011-03-08 | 2016-06-01 | Sanofi | Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof |
| EP2683700B1 (en) | 2011-03-08 | 2015-02-18 | Sanofi | Tetra-substituted oxathiazine derivatives, method for their preparation, their usage as medicament and medicament containing same and its use |
| WO2012120053A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| WO2012120055A1 (en) | 2011-03-08 | 2012-09-13 | Sanofi | Di- and tri-substituted oxathiazine derivates, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2805818B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | AZETIDINE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| FR2805810B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING 3- AMINO-AZETIDINE DERIVATIVES, THE NEW DERIVATIVES AND THEIR PREPARATION |
| FR2805817B1 (en) * | 2000-03-03 | 2002-04-26 | Aventis Pharma Sa | PHARMACEUTICAL COMPOSITIONS CONTAINING AZETIDINE DERIVATIVES, NOVEL AZETIDINE DERIVATIVES AND THEIR PREPARATION |
| US7485732B2 (en) * | 2003-06-11 | 2009-02-03 | Merck & Co., Inc. | Substituted 3-alkyl and 3-alkenyl azetidine derivatives |
| CN101426500A (en) * | 2005-05-02 | 2009-05-06 | 默克公司 | Combination of dipeptidyl peptidase-iv inhibitor and a cannabinoid cb1 receptor antagonist for the treatment of diabetes and obesity |
-
2006
- 2006-11-20 AR ARP060105076A patent/AR058199A1/en unknown
- 2006-11-22 EP EP06838347A patent/EP1954692A1/en not_active Withdrawn
- 2006-11-22 WO PCT/US2006/045328 patent/WO2007062193A1/en active Application Filing
- 2006-11-22 BR BRPI0619018A patent/BRPI0619018A2/en not_active IP Right Cessation
- 2006-11-22 TW TW095143274A patent/TW200804317A/en unknown
- 2006-11-22 RU RU2008126248/04A patent/RU2008126248A/en not_active Application Discontinuation
- 2006-11-22 KR KR1020087012880A patent/KR20080073721A/en not_active Application Discontinuation
- 2006-11-23 DO DO2006000261A patent/DOP2006000261A/en unknown
- 2006-11-23 PE PE2006001495A patent/PE20070647A1/en not_active Application Discontinuation
-
2008
- 2008-05-20 IL IL191586A patent/IL191586A0/en unknown
- 2008-05-22 CR CR10014A patent/CR10014A/en not_active Application Discontinuation
- 2008-05-27 EC EC2008008477A patent/ECSP088477A/en unknown
- 2008-05-28 SV SV2008002917A patent/SV2009002917A/en not_active Application Discontinuation
- 2008-06-25 MA MA31075A patent/MA30086B1/en unknown
- 2008-06-27 NO NO20082919A patent/NO20082919L/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1954692A1 (en) | 2008-08-13 |
| DOP2006000261A (en) | 2007-07-15 |
| CR10014A (en) | 2008-07-29 |
| AR058199A1 (en) | 2008-01-23 |
| ECSP088477A (en) | 2008-06-30 |
| BRPI0619018A2 (en) | 2016-11-29 |
| RU2008126248A (en) | 2010-01-10 |
| MA30086B1 (en) | 2008-12-01 |
| KR20080073721A (en) | 2008-08-11 |
| PE20070647A1 (en) | 2007-08-11 |
| WO2007062193A1 (en) | 2007-05-31 |
| SV2009002917A (en) | 2009-02-19 |
| IL191586A0 (en) | 2008-12-29 |
| TW200804317A (en) | 2008-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20082919L (en) | Heterosubstituted 3-alkylazetidine derivatives | |
| DE60316829D1 (en) | SUBSTITUTED FUROÄ2,3-BÜPYRIDINE DERIVATIVES | |
| NO20060141L (en) | Substituted 3-alkyl and 3-alkenylazetidine derivatives | |
| DE60334787D1 (en) | SUBSTITUTED AMIDE | |
| JO2482B1 (en) | Substituted amids | |
| WO2003082190A3 (en) | Spirocyclic amides as cannabinoid receptor modulators | |
| WO2003063781A3 (en) | Substituted imidazoles as cannabinoid receptor modulators | |
| WO2004058145A3 (en) | Substituted amides | |
| WO2004029204A3 (en) | Substituted pyrimidines | |
| AU2016299485B2 (en) | 1,3,4-oxadiazole amide derivative compound as histone deacetylase 6 inhibitor, and pharmaceutical composition containing same | |
| ATE452890T1 (en) | SUBSTITUTED NAPHTHYRIDINONE DERIVATIVES | |
| WO2003086288A3 (en) | Bicyclic amides | |
| WO2005027837A3 (en) | Substituted sulfonamides | |
| WO2003082191A3 (en) | Substituted 2,3-diphenyl pyridines | |
| ATE501151T1 (en) | SUBSTITUTED PYRANO Ä2, 3 - BUPYRIDINE DERIVATIVES AS CANNABINOID-1 RECEPTOR MODULATORS | |
| WO2008024284A3 (en) | Sulfonylated piperazines as cannabinoid-1 receptor modulators | |
| NO20063381L (en) | CB1 modulator connections | |
| WO2007064566A3 (en) | Heterocycle-substituted 3-alkyl azetidine derivatives | |
| NO20054206L (en) | biphenyl | |
| WO2007136607A3 (en) | Substituted esters as cannabinoid-1 receptor modulators | |
| WO2007079163A3 (en) | Prokineticin 1 receptor antagonists | |
| WO2004069794A3 (en) | New arylpiperazinyl compounds | |
| TW200400185A (en) | Derives de 1-piperazinylacylpiperidine substitues, leur preparation et leur application en therapeutique | |
| WO2006041797A3 (en) | Acyclic hydrazides as cannabinoid receptor modulators | |
| ATE486078T1 (en) | 5,6-DISUBSTITUTED OXADIAZOLOPYRAZINE AND THIADIAZOLOPYRAZINE AS LIGANDS OF THE CXC CHEMOKINE RECEPTOR |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |